Studies have shown Trio overexpression and (or) mutations in esophageal squamous cell carcinoma, NSCLC, stomach cancer, endometrial cancer, colorectal cancer, and glioblastoma (Table 1) (Schmidt et al., 2014). This evidence concerns the gene TRIO and glioblastoma.